Fractionation of Bioactive Polysaccharides from Volvariella volvacea and Their Ameliorative Effects on Hepatic Lipid Accumulation
- 1School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China
- 2School of Pharmaceutical Sciences, Nanjing University of Chinese Medicine, Nanjing 210023, China
Abstract
Volvariella volvacea is a widely consumed edible mushroom, yet the lipid-lowering potential of its polysaccharides remains poorly understood. In this study, two polysaccharide-enriched fractions, VVP-1 and VVP-2, were isolated from V. volvacea fruiting bodies, with weight-average molecular weights of 13,789 and 17,829 Da, respectively. Their lipid-lowering effects were evaluated in palmitic acid (PA)-challenged AML12 mouse hepatocytes and in high-fat diet (HFD)-induced obese male C57BL/6J mice. Both fractions reduced PA-induced intracellular triglyceride (TG) levels in a dose-dependent manner, with VVP-2 showing a trend of greater efficacy. At the molecular level, VVP-2 exposure was associated with downregulation of the lipogenic genes Acaca and Srebf1, upregulation of the fatty acid oxidation-related genes Cpt1a and Ppara, decreased secretion of TNF-α, IL-6, and IL-1β, preservation of mitochondrial signal, restoration of mitochondrial membrane potential, and enhanced ATP production. In HFD-fed mice, VVP-2 (100 mg/kg) attenuated body-weight gain by 38.9%, reduced liver weight by 28.9% and epididymal, inguinal, and perirenal fat weights by 50.3%, 47.5%, and 28.8%, respectively, improved the serum lipid profile (TG reduced by 39.1%, TC by 33.5%, NEFA by 56.2%, and LDL-C by 56.8%), and alleviated hepatic lipid accumulation and liver injury. These findings suggest that VVP-2 may improve mitochondrial function and modulate lipid metabolism-related gene expression, potentially reducing lipid accumulation and inflammation in hepatocytes. These results support the potential of VVP-2 as a lipid-lowering functional food ingredient for the prevention of metabolic dysfunction-associated steatotic liver disease.
Related
- Structural control over equilibrium silicon and oxygen isotopic fractionation: A first-principles density-functional theory study
- Zn isotope fractionation during interaction with phototrophic biofilm
- FAIMS-GPF XL-MS: crosslinking-mass spectrometry based on gas-phase fractionation
- Novel polysaccharides from Metarhizium pinghaense modulate bovine satellite cell fate for cultured meat production
- Natural polysaccharides as modulators of mitochondrial homeostasis: structural determinants, pharmacological mechanisms, and translational challenges
BibTeX
@article{xia2026fractionation,
title = {{Fractionation of Bioactive Polysaccharides from Volvariella volvacea and Their Ameliorative Effects on Hepatic Lipid Accumulation}},
author = {Wenbo Xia and Ruohan Zhao and Shuying Li},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27219750},
url = {https://www.mdpi.com/1422-0067/27/21/9750},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Fractionation of Bioactive Polysaccharides from Volvariella volvacea and Their Ameliorative Effects on Hepatic Lipid Accumulation
AU - Wenbo Xia
AU - Ruohan Zhao
AU - Shuying Li
PY - 2026
DA - 2026/10/30
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27219750
UR - https://www.mdpi.com/1422-0067/27/21/9750
AB - Volvariella volvacea is a widely consumed edible mushroom, yet the lipid-lowering potential of its polysaccharides remains poorly understood. In this study, two polysaccharide-enriched fractions, VVP-1 and VVP-2, were isolated from V. volvacea fruiting bodies, with weight-average molecular weights of 13,789 and 17,829 Da, respectively. Their lipid-lowering effects were evaluated in palmitic acid (PA)-challenged AML12 mouse hepatocytes and in high-fat diet (HFD)-induced obese male C57BL/6J mice. Both fractions reduced PA-induced intracellular triglyceride (TG) levels in a dose-dependent manner, with VVP-2 showing a trend of greater efficacy. At the molecular level, VVP-2 exposure was associated with downregulation of the lipogenic genes Acaca and Srebf1, upregulation of the fatty acid oxidation-related genes Cpt1a and Ppara, decreased secretion of TNF-α, IL-6, and IL-1β, preservation of mitochondrial signal, restoration of mitochondrial membrane potential, and enhanced ATP production. In HFD-fed mice, VVP-2 (100 mg/kg) attenuated body-weight gain by 38.9%, reduced liver weight by 28.9% and epididymal, inguinal, and perirenal fat weights by 50.3%, 47.5%, and 28.8%, respectively, improved the serum lipid profile (TG reduced by 39.1%, TC by 33.5%, NEFA by 56.2%, and LDL-C by 56.8%), and alleviated hepatic lipid accumulation and liver injury. These findings suggest that VVP-2 may improve mitochondrial function and modulate lipid metabolism-related gene expression, potentially reducing lipid accumulation and inflammation in hepatocytes. These results support the potential of VVP-2 as a lipid-lowering functional food ingredient for the prevention of metabolic dysfunction-associated steatotic liver disease.
SN - 1422-0067
ER -